Publications by authors named "Kirk D Robarge"

Claim this Profile
S
Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
Kirk D Robarge, Wendy Lee, Charles Eigenbrot, Mark Ultsch, Christian Wiesmann

Bioorg Med Chem Lett· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Wendy Lee, Daniel F Ortwine, Philippe Bergeron, Kevin Lau, Lichuan Lin, Kirk D Robarge

Bioorg Med Chem Lett· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Frederick Cohen, Philippe Bergeron, Elizabeth Blackwood, Krista K Bowman, Huifen Chen, Kirk D Robarge

J Med Chem· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
Georgette M Castanedo, Shumei Wang, Kirk D Robarge, Elizabeth Blackwood, Daniel Burdick

Bioorg Med Chem Lett· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDC-0449-a potent inhibitor of the hedgehog pathway.
Kirk D Robarge, Shirley A Brunton, Georgette M Castanedo, Yong Cui, Michael S Dina

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis